RUNX1 and acute lymphoblastic leukemia: The findings presented here suggest that BET inhibition led to a reduction in H3K27ac levels preferentially at the BRD4 enriched regions and disrupted RUNX1 driven super-enhancers, suggesting a therapeutic opportunity to target RUNX1 driven enhancers in T-ALL.